NIBEC is applying its PDC concept to oncology and beyond. For example, the company is developing an NIPEP-TPP anti-mutant KRAS antibody that binds the G12C mutant form of the human KRAS protein ...

One global pharma company has already formed a collaboration agreement around two drug candidates of Libera Bio, using the MPN Technology to deliver anti-KRAS monoclonal antibodies into cells for ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...